Going from one field to the next can be a tricky thing to navigate. In this episode of Trends from the Trenches, host Stan Gloss speaks with Tom Miller, Co-Founder and CEO of Iambic Therapeutics, about his journey from academia as a professor at the California Institute of Technology to getting B-Round funding as the CEO of his own start-up. Miller discusses why he started his company, what inspired him to turn his research into an entrepreneurial venture, and how combining physics and data can create more data-efficient AI algorithms that vastly improve accuracy in prediction models. Miller also shares advice and insights for academic researchers on taking their discoveries and bringing them to the market.
Tom Miller, Co-Founder and CEO, Iambic Therapeutics
Tom Miller is a scientist and entrepreneur with a focus on the nexus of AI, chemistry, and biology. He joined the Caltech faculty in 2008 and was promoted to full professor in 2013. He’s published more than 130 peer-reviewed articles and patents and received numerous awards for research excellence. In 2020, Tom co-founded and became CEO of Iambic Therapeutics, a technology-driven biopharma that is disrupting the therapeutics landscape with its generative AI drug discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and seasoned drug hunters with strong track records of success in delivering clinically validated breakthrough treatments. The Iambic platform has been demonstrated to deliver high quality, differentiated drugs to clinic with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing an internal pipeline of clinical assets to address unmet patient need across therapeutics areas.
